Suraksha Diagnostic Limited

Suraksha Diagnostic Limited is a diagnostics company incorporated in 2005 and headquartered in Kolkata, West Bengal. It provides integrated pathology, radiology and medical consultation services through a network built around a central reference laboratory, several satellite laboratories, and over 200 customer touchpoints including diagnostic centres and sample collection centres, offering more than 2,300 specialised tests. The company's operations are concentrated in eastern and northeastern India, spanning West Bengal, Bihar, Assam and Meghalaya, and it also runs a number of polyclinics offering in-house medical consultations alongside its core testing business. Its laboratory operations carry accreditation from bodies such as the College of American Pathologists and NABL, supporting the reliability of its testing services. The IPO itself was structured entirely as an offer for sale by the company's promoters and another selling shareholder, so Suraksha Diagnostic received no proceeds from the issue. The company operates in a fragmented regional diagnostics market alongside larger national players such as Dr Lal PathLabs, Metropolis Healthcare, Thyrocare and Vijaya Diagnostic Centre, with its scale concentrated specifically in the east of the country.

The anchor book raised about Rs 254 crore ahead of the issue opening, with shares allotted at the upper price band of Rs 441 per share. Nippon Life India, Kotak Mutual Fund, Aditya Birla Sun Life Trustee and Quant Mutual Fund each picked up shares worth about Rs 35 crore, Carnelian Bharat Amritkaal Fund invested about Rs 30 crore, and other participants included Mirae Asset, JM Financial, Bandhan Mutual Fund and Societe Generale.